INC Research Appoints Gregory M. Hockel, PhD to Lead Regulatory Consulting Practice

Provides global leadership for group guiding Company’s biopharmaceutical customers through regulatory approvals worldwide

Raleigh, N.C., Nov. 18, 2013 – INC Research<>, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the appointment of Gregory M. Hockel, PhD, as Senior Vice President, Regulatory Consulting. Based in Maryland near the FDA headquarters, Dr. Hockel will leverage his extensive regulatory expertise to lead the Company’s global Regulatory Consulting organization. His team will be responsible for assisting customers with product development and regulatory approvals worldwide.

“Greg is an exceptionally experienced regulatory expert with more than three decades of thought leadership in the pharmaceutical industry,” said Alistair Macdonald, Chief Operating Officer. “He has overseen the submission of more than 150 INDs and consulted on more than 40 NDAs/BLAs/CTDs. His expertise increases our ability to look across the strategic plans of our customers and advise them on the best regulatory strategies for gaining approval. The addition of Greg to our already strong team increases the strategic regulatory insights INC Research can offer to our customers.”

Prior to joining INC Research, Dr. Hockel spent more than 14 years in senior positions with inVentiv Health Clinical (formerly PharmaNet). He holds a doctorate in physiology from the Indiana University School of Medicine and his training also includes a postdoctoral fellowship with the University of Mississippi School of Medicine Department of Physiology and Biophysics.

Dr. Hockel also holds a master’s degree in business administration from the Rensselaer Polytechnic Institute. He is active in multiple professional organizations, including the Drug Information Association (DIA) and the Association of Clinical Research Organizations (ACRO), and is an accomplished speaker and author, contributing his expertise to a wide array of industry conferences and trade publications.

With a network of global locations and on-the-ground expertise in all key markets, INC Research is committed to delivering superior regulatory services to help customers design the most efficient product development programs. The Company supports customer needs across the entire product lifecycle, from early regulatory development strategy consultations (FDA/Scientific Advice meetings) to clinical trial and marketing authorization submissions and post-licensing support. INC Research's service portfolio ranges from new chemical entities (NCEs) to biologics, biosimilars, well-established substances (505(b)(2) pathway), generic drugs, devices and in vitro diagnostics. For more information on INC Research's Regulatory Consulting services, please visit the online Resource Library<


Posted: December 2013

View comments